|
US7270971B2
(en)
*
|
2003-10-16 |
2007-09-18 |
Merck & Co., Inc. |
Fluorescence assay for measuring the rate of cholesterol ester transfer
|
|
DOP2005000123A
(es)
*
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
AU2006265975B2
(en)
*
|
2005-07-01 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Process for synthesizing a CETP inhibitor
|
|
ATE516016T1
(de)
|
2005-12-05 |
2011-07-15 |
Merck Sharp & Dohme |
Selbstemulgierende formulierungen von cetp- hemmern
|
|
AR057218A1
(es)
*
|
2005-12-15 |
2007-11-21 |
Astra Ab |
Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
|
|
US8865707B2
(en)
*
|
2005-12-30 |
2014-10-21 |
Merck Sharp & Dohme Corp. |
Cholesteryl ester transfer protein inhibitors
|
|
JP5040036B2
(ja)
|
2005-12-30 |
2012-10-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体
|
|
US7781426B2
(en)
*
|
2005-12-30 |
2010-08-24 |
Merck Sharp & Dohme Corp. |
CETP inhibitors
|
|
WO2007081569A2
(en)
*
|
2005-12-30 |
2007-07-19 |
Merck & Co., Inc. |
Cetp inhibitors
|
|
CN101378731B
(zh)
*
|
2006-02-09 |
2014-03-05 |
默沙东公司 |
Cetp抑制剂的聚合物制剂
|
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
WO2007136672A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Merck & Co., Inc. |
Synthesis of a biaryl synthetic intermediate
|
|
WO2008082567A1
(en)
*
|
2006-12-29 |
2008-07-10 |
Merck & Co., Inc. |
Process for synthesizing a cetp inhibitor
|
|
US8168815B2
(en)
|
2007-01-26 |
2012-05-01 |
Kaneq Pharma Inc. |
Fused aromatic PTP-1B inhibitors
|
|
CA2681628C
(en)
*
|
2007-03-16 |
2016-10-18 |
Concert Pharmaceuticals, Inc. |
Inhibitors of cholesterol ester transfer protein
|
|
EP2155187B1
(en)
|
2007-05-07 |
2016-05-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
|
ES2569660T3
(es)
|
2007-06-08 |
2016-05-12 |
Mannkind Corporation |
Inhibidores de la IRE-1alfa
|
|
JP2010530418A
(ja)
*
|
2007-06-20 |
2010-09-09 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
|
|
CA2689523A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
JP2010530416A
(ja)
*
|
2007-06-20 |
2010-09-09 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
|
|
RU2010103104A
(ru)
|
2007-07-02 |
2011-08-10 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Производные имидазола в качестве антагонистов рецептора ccr2
|
|
JP5451611B2
(ja)
*
|
2007-07-26 |
2014-03-26 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
|
|
AR069207A1
(es)
*
|
2007-11-07 |
2010-01-06 |
Vitae Pharmaceuticals Inc |
Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
|
|
CA2708303A1
(en)
|
2007-12-11 |
2009-06-18 |
Vitae Pharmaceuticals, Inc. |
Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
|
|
TW200934490A
(en)
*
|
2008-01-07 |
2009-08-16 |
Vitae Pharmaceuticals Inc |
Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
|
|
WO2009094169A1
(en)
*
|
2008-01-24 |
2009-07-30 |
Vitae Pharmaceuticals, Inc. |
Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
EP2245002A4
(en)
*
|
2008-02-01 |
2011-08-17 |
Amira Pharmaceuticals Inc |
AMINOALKYLBIPHENYL ANTAGONISTS N, N 'DISUBSTITUTED FROM D2 RECEPTORS OF PROSTAGLANDIN
|
|
US8067445B2
(en)
*
|
2008-02-01 |
2011-11-29 |
Panmira Pharmaceuticals, Llc |
N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
|
|
CA2714532A1
(en)
*
|
2008-02-11 |
2009-08-20 |
Vitae Pharmaceuticals, Inc. |
1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
|
|
EP2257536A4
(en)
|
2008-02-14 |
2011-03-23 |
Amira Pharmaceuticals Inc |
CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
|
|
US8598160B2
(en)
*
|
2008-02-15 |
2013-12-03 |
Vitae Pharmaceuticals, Inc. |
Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
|
|
US8497381B2
(en)
|
2008-02-25 |
2013-07-30 |
Panmira Pharmaceuticals, Llc |
Antagonists of prostaglandin D2 receptors
|
|
CA2718264A1
(en)
*
|
2008-03-18 |
2009-09-24 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
US8426449B2
(en)
|
2008-04-02 |
2013-04-23 |
Panmira Pharmaceuticals, Llc |
Aminoalkylphenyl antagonists of prostaglandin D2 receptors
|
|
TW201004945A
(en)
|
2008-05-01 |
2010-02-01 |
Vitae Pharmaceuticals Inc |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
KR20110002492A
(ko)
|
2008-05-01 |
2011-01-07 |
비타이 파마슈티컬즈, 인코포레이티드 |
11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
|
|
EP2291370B1
(en)
|
2008-05-01 |
2013-11-27 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
US8063088B2
(en)
*
|
2008-06-11 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Imidazolidine derivatives
|
|
US8846668B2
(en)
|
2008-07-25 |
2014-09-30 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
CA2729993A1
(en)
|
2008-07-25 |
2010-01-28 |
Boehringer Ingelheim International Gmbh |
Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
WO2010011314A1
(en)
|
2008-07-25 |
2010-01-28 |
Boehringer Ingelheim International Gmbh |
Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
|
|
GB2463788B
(en)
|
2008-09-29 |
2010-12-15 |
Amira Pharmaceuticals Inc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
DE102008049675A1
(de)
|
2008-09-30 |
2010-04-01 |
Markus Dr. Heinrich |
Verfahren zur Herstellung von 3-Aminobiphenylen
|
|
WO2010039977A2
(en)
|
2008-10-01 |
2010-04-08 |
Amira Pharmaceuticals, Inc. |
Heteroaryl antagonists of prostaglandin d2 receptors
|
|
US8354454B2
(en)
*
|
2008-10-01 |
2013-01-15 |
Merck Sharp & Dohme Corp. |
Prodrugs of oxazolidinone CETP inhibitors
|
|
US8524748B2
(en)
|
2008-10-08 |
2013-09-03 |
Panmira Pharmaceuticals, Llc |
Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
|
|
US8410284B2
(en)
|
2008-10-22 |
2013-04-02 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US8383654B2
(en)
|
2008-11-17 |
2013-02-26 |
Panmira Pharmaceuticals, Llc |
Heterocyclic antagonists of prostaglandin D2 receptors
|
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
WO2010085528A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
|
EP2389226B1
(en)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
|
JP5679997B2
(ja)
|
2009-02-04 |
2015-03-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
|
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
|
UA109255C2
(ru)
|
2009-04-30 |
2015-08-10 |
Берінгер Інгельхайм Інтернешнл Гмбх |
Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
|
|
WO2011011123A1
(en)
|
2009-06-11 |
2011-01-27 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
|
|
WO2011002910A1
(en)
|
2009-07-01 |
2011-01-06 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
KR20120047273A
(ko)
*
|
2009-08-05 |
2012-05-11 |
판미라 파마슈티칼스, 엘엘씨 |
Ｄｐ2 길항제 및 이의 용도
|
|
JP2011057661A
(ja)
|
2009-08-14 |
2011-03-24 |
Bayer Cropscience Ag |
殺虫性カルボキサミド類
|
|
EP2496589B1
(en)
|
2009-11-05 |
2014-03-05 |
Boehringer Ingelheim International GmbH |
Novel chiral phosphorus ligands
|
|
EP2523558A4
(en)
|
2010-01-15 |
2013-06-19 |
Merck Sharp & Dohme |
OXADIAZOL BETA CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
EP2576570A1
(en)
|
2010-05-26 |
2013-04-10 |
Boehringer Ingelheim International GmbH |
2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
|
|
EP2397473A1
(en)
|
2010-06-14 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
A stable highly crystalline anacetrapib
|
|
EP2582698B1
(en)
|
2010-06-16 |
2016-09-14 |
Vitae Pharmaceuticals, Inc. |
Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
|
|
WO2011161128A1
(en)
|
2010-06-25 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
|
|
JPWO2012046681A1
(ja)
|
2010-10-04 |
2014-02-24 |
興和株式会社 |
脂質代謝関連ｍＲＮＡの発現抑制剤
|
|
CA2814846A1
(en)
*
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted oxazolidinone cetp inhibitor
|
|
CA2813671A1
(en)
|
2010-11-02 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
EP2468736A1
(en)
*
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
EP2468735A1
(en)
*
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
US9052326B2
(en)
|
2011-01-26 |
2015-06-09 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Method for assessing a subject's risk of having a cardiovascular disease
|
|
CA2826649C
(en)
|
2011-02-25 |
2016-07-26 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
PH12013501829A1
(en)
*
|
2011-04-12 |
2015-10-23 |
Chong Kun Dang Pharmaceutical Corp |
Cycloalkenyl aryl derivatives for cetp inhibitor
|
|
CN103813789A
(zh)
*
|
2011-07-07 |
2014-05-21 |
持田制药株式会社 |
含有高纯度epa的抗肥胖药
|
|
CN103648495A
(zh)
|
2011-07-08 |
2014-03-19 |
诺华股份有限公司 |
在高甘油三酯对象中治疗动脉粥样硬化的方法
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
WO2013066768A1
(en)
*
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Process for a cetp inhibitor
|
|
WO2013064188A1
(en)
|
2011-11-03 |
2013-05-10 |
Lek Pharmaceuticals D.D. |
A stable highly crystalline anacetrapib
|
|
WO2013080999A1
(ja)
|
2011-11-29 |
2013-06-06 |
興和株式会社 |
ＮＰＣ１Ｌ１及び／又はＬＩＰＧ ｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤
|
|
KR101436547B1
(ko)
*
|
2011-11-30 |
2014-09-02 |
주식회사 대웅제약 |
고지혈증의 예방 또는 치료용 약학 조성물
|
|
WO2013091696A1
(en)
*
|
2011-12-21 |
2013-06-27 |
Lek Pharmaceuticals D.D. |
Synthesis of intermediates for preparing anacetrapib and derivatives thereof
|
|
WO2013165854A1
(en)
*
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted heterocyclic cetp inhibitors
|
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
|
CN103958484B
(zh)
*
|
2012-07-19 |
2015-11-25 |
上海恒瑞医药有限公司 |
噁唑烷酮类衍生物、其制备方法及其在医药上的应用
|
|
EP2888006B1
(en)
|
2012-08-22 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives useful as ampk activators
|
|
EP2934518B1
(en)
|
2012-12-19 |
2020-02-19 |
Merck Sharp & Dohme Corp. |
Spirocyclic cetp inhibitors
|
|
WO2014099834A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Therapeutic thiazolidinone compounds
|
|
WO2014111953A1
(en)
*
|
2013-01-17 |
2014-07-24 |
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited |
Process for preparation of anacetrapib and intermediates thereof
|
|
AU2014213125B2
(en)
*
|
2013-01-31 |
2016-06-02 |
Chong Kun Dang Pharmaceutical Corp. |
Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
EP3027619B1
(en)
|
2013-07-30 |
2019-01-02 |
Merck Sharp & Dohme Corp. |
Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
|
|
US9688630B2
(en)
|
2013-10-10 |
2017-06-27 |
Merck Sharp & Dohme Corp. |
3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
|
|
US9663534B2
(en)
|
2013-12-17 |
2017-05-30 |
Merck Sharp & Dohme Corp. |
Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
CN104955816B
(zh)
*
|
2014-01-14 |
2016-08-31 |
杭州普晒医药科技有限公司 |
一种安塞曲匹的晶型及其制备方法、其药物组合物和用途
|
|
CN103923030B
(zh)
*
|
2014-03-27 |
2015-07-22 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的关键中间体的合成方法
|
|
CN103923031A
(zh)
*
|
2014-04-01 |
2014-07-16 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的中间体的合成方法
|
|
EP3174537B1
(en)
|
2014-07-29 |
2021-06-23 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
WO2016016157A1
(en)
|
2014-07-30 |
2016-02-04 |
F. Hoffmann-La Roche Ag |
Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
|
|
CN104230835B
(zh)
*
|
2014-09-01 |
2017-01-25 |
福建师范大学 |
一种合成n‑苯乙烯基恶唑烷‑2‑酮衍生物的方法
|
|
WO2016067194A1
(en)
*
|
2014-10-27 |
2016-05-06 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of anacetrapib and an intermediate thereof
|
|
CN106032362B
(zh)
*
|
2015-03-10 |
2018-06-19 |
湖南千金湘江药业股份有限公司 |
安塞曲匹的制备方法
|
|
MX2018015872A
(es)
|
2016-06-29 |
2019-04-22 |
Orion Corp |
Derivados de benzodioxano y su uso farmaceutico.
|
|
WO2018016743A1
(ko)
*
|
2016-07-19 |
2018-01-25 |
재단법인 대구경북첨단의료산업진흥재단 |
Cetp 억제제로서의 옥사졸리딘온 유도체 화합물
|
|
US10851059B2
(en)
*
|
2016-08-17 |
2020-12-01 |
Novartis Ag |
Processes and intermediates for NEP inhibitor synthesis
|
|
CN106496154A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
安塞曲匹的制备方法
|
|
CN106496211A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
二氟甲基取代的噁唑烷酮化合物及其用途
|
|
CN106749075A
(zh)
*
|
2016-11-24 |
2017-05-31 |
山东新华制药股份有限公司 |
阿那曲波的恶唑烷酮中间体的晶型及其制备方法
|
|
US20190070178A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
JP2021534236A
(ja)
|
2018-08-09 |
2021-12-09 |
ダルコア ファーマ ユーケー リミテッド，レザーヘッド，ツーク ブランチ |
新規発症２型糖尿病の発生遅延並びに２型糖尿病の進行緩徐化及び治療の方法
|
|
SG11202107468YA
(en)
|
2019-03-07 |
2021-08-30 |
Dalcor Pharma Uk Ltd Leatherhead |
Methods for treating or preventing heart failure and reducing risk of heart failure
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
JP7675061B2
(ja)
|
2019-07-19 |
2025-05-12 |
バイオシント アクチェンゲゼルシャフト |
ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用
|
|
WO2021226208A2
(en)
|
2020-05-05 |
2021-11-11 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|
|
KR102698413B1
(ko)
|
2020-05-05 |
2024-08-26 |
뉴베일런트, 아이엔씨. |
헤테로방향족 거대환식 에터 화학치료제
|
|
WO2022075645A1
(ko)
*
|
2020-10-08 |
2022-04-14 |
재단법인 대구경북첨단의료산업진흥재단 |
Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물
|
|
WO2023278698A1
(en)
*
|
2021-06-30 |
2023-01-05 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
TW202320768A
(zh)
|
2021-10-01 |
2023-06-01 |
美商努法倫特公司 |
雜芳族大環醚化合物之固體形式、醫藥組成物及製備
|
|
WO2025093129A1
(en)
|
2023-11-01 |
2025-05-08 |
Newamsterdam Pharma B.V. |
Treatment and prevention of age-related macular degeneration using a cetp inhibitor
|